肿瘤多药耐药机制的研究进展

doi:10.11904/j.issn.1002-3070.2015.04.017

实用肿瘤学杂志 ›› 2015, Vol. 29 ›› Issue (4): 364-367.doi: 10.11904/j.issn.1002-3070.2015.04.017

肿瘤多药耐药机制的研究进展

张伟综述,吴瑾审校

哈尔滨医科大学附属肿瘤医院(哈尔滨 150081)

收稿日期:2015-01-16 出版日期:2015-08-27 发布日期:2015-08-27
通讯作者: 吴瑾 E-mail:w.u_jin@163.com
作者简介:张伟,女(1988-),硕士研究生,从事肿瘤内科的研究
基金资助:
黑龙江省教育厅2013年度科学技术项目(12531243)

The research progress on cancer multidrug resistance mechanisms

ZHANG Wei,WU Jin

The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081,China

Received:2015-01-16 Online:2015-08-27 Published:2015-08-27

摘要/Abstract

摘要： 肿瘤多药耐药已成为肿瘤化疗成功与否的关键因素之一,因此克服肿瘤多药耐药是肿瘤治疗的当务之急。肿瘤多药耐药机制是一个十分复杂的过程,受多种因素影响。因此,对肿瘤多药耐药机制进行深入研究将有助于筛选出更加合适的抗肿瘤药物。本文就近年来肿瘤多药耐药机制的研究进展做一综述。

关键词: 肿瘤, 多药耐药, 机制

Abstract: The multidrug resistance(MDR)has become one of the key factors in the success of chemotherapy.Thus,overcoming multidrug resistance of tumor has become a pressing matter of the moment for tumor therapy.The mechanism of MDR is a very complicated process,influenced by many factors.Therefore,the tumor multidrug resistance mechanisms in depth study will help to select more appropriate anti-tumor drugs.In this review,we described about MDR mechanisms researching progress in recent years.

Key words: Cancer, Multidrug resistance, Mechanism

中图分类号:

R730.53

张伟,吴瑾. 肿瘤多药耐药机制的研究进展[J]. 实用肿瘤学杂志, 2015, 29(4): 364-367.

ZHANG Wei,WU Jin. The research progress on cancer multidrug resistance mechanisms[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 364-367.

参考文献

1 Boyle P,Levin B.World Cancer Report 2008[M].Lyon:International Agency for Research on Cancer(IARC),2008:14-15.
2 Kibria G,Hatakeyama H,Harashima H.Cancer multidrug resistance:mechanisms involved and strategies for circumvention using a drug delivery system[J].Arch Pharm Res,2014,37(1):4-15.
3 Juliano RL,Ling V.A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J].Biochem Biophys Acta,1976,455(1):152-162.
4 Andorfer P,Rotheneder H.Regulation of the MDR1 promoter by E2F1and EAPP[J].FEBS Lett,2013,587(10):1504-1509.
5 Amiri-Kordestani L,Basseville A,Kurdziel K,et al.Targeting MDR in breast and lung cancer:discriminating its potential importance from the failure of drug resistance reversal studies[J].Drug Resist Updat,2012,15(1-2):50-61.
6 Mao QC,Jashvant D.Role of the breast cancer resistance protein(BCRP/ABCG2)in drug transport-an update[J].The AAPS Journal,2015,17(1):65-82.
7 Azab F,Vali S,Abraham J,et al.PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation,synergizes with other therapies and overcomes stroma-induced resistance[J].Brit J Haematol,2014,165(1):89-101.
8 Kanwar JS,Kamalapuram R,Kanwar RK.Targeting survivin in cancer:The cell-signalling perspective[J].Drug Discovery Today,2011,16(11-12):485-494.
9 Vinod BS,Maliekal TT,Anto RJ.Phytochemicals as chemosensitizers:from molecular mechanism to clinical significance[J].Antioxid Redox Signal,2013,18(11):1307-1348.
10 O′Donovan TR,O′Sullivan GC,McKenna SL,Induction of autophagy by drug resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics[J].Autophagy,2011,7(5):509-524.
11 Guo XL,Hu F,Zhang SS,et al,Inhibition of p53 increases chemosensitivity to 5-FU in nutrient-deprived hepatocarcinoma cells by suppressing autophagy[J].Cancer Lett,2014,346(2):278-284.
12 Wu Q,Yang Z,Nie Y,et al.Multi-drug resistance in cancer chemotherapeutics:Mechanisms and lab approaches[J].Cancer Letters,2014,347(2):159-166.
13 Xue Z,Yan H,Li J,et al.Identification of cancer stem cells in vincristine preconditioned SGC7901 gastric cancer cell line[J].Cell Biochem,2012,113(1):302-312.
14 Sarvi S,Mackinnon AC,Avlonitis N,et al.CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist[J].Cancer Res,2014,74(5):1554-1565.
15 Martin V,Sanchez-Sanchez AM,Herrera F,et al.Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells[J].Br J Cancer,2013,108(10):2005-2012.
16 Cheng W,Liu T,Wan X,et al,MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancerinitiating cells[J].FEBS,2012,279(11):2047-2059.
17 张超,杨春辉,孟秀香.Bmi-1基因与肿瘤多药耐药性的关系[J].实用肿瘤学杂志,2013,27(4):367-371.
18 Wang F,Li T,Zhang B,et al.MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN[J].Biochem Biophys Res Commun,2013,434(3):688-694.
19 Chen Q,Xia HW,Ge XJ,et al.Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases[J].Cancer Prev,2013,14(12):7421-7426.
20 吴哲明,程丽.HIF-1α对恶性肿瘤发展及多药耐药调控机制的研究进展[J].实用肿瘤学杂志,2012,26(5):469-473.
21 Li DW,Dong P,Wang F,et al.Hypoxia induced multidrug resistance of laryngeal cancer cells via Hypoxia-inducible factor-1α[J].Asian Pac J Cancer Prev,2013,14(8):4853-4858.
22 Chen J,Ding Z,Peng Y,et al.HIF-1α Inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein[J].PLoS One,2014,9(6):e98882.
23 Casorelli I,Bossa C,Bignami M.DNA damage and repair in human cancer:molecular mechanisms and contribution to therapy-related leukemias[J].Environ Res Public Health,2012,9(8):2636-2657.
24 Ziebarth AJ,Nowsheen S,Steg AD,et al.(CD105)contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer[J].Clin Cancer Res,2013,19(1):170-182.
25 Williamson EA,Damiani L,Leitao A,et al.Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy[J].Cancer Res,2012,72(23):6200-6208.
26 王清,刘倩,张学梅.P-糖蛋白及其逆转肿瘤细胞多药耐药性的研究进展[J].中国执业药师,2013,3(5):33-36.
27 Kasuya K,Tsuchida A,Suzuki M,et al.Single nucleotide polymorphism of multidrug-resistance 1 and anti-multidrug-resistance 1 single chain antibody treatment for the pancreatic cancer cell line[J].Hepatogastroenterology,2012,59(113):272-275.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[3]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[4]	刘乙澍,曲国蕃. 长链非编码RNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 266-270.
[5]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[6]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[7]	徐晖, 李希, 周春水. 应用以人转录组为靶点的shRNA文库筛选肺癌肿瘤相关抑制基因[J]. 实用肿瘤学杂志, 2019, 33(2): 97-102.
[8]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[9]	常晓霞综述, 宋冰冰, 刘家仁审校. 植物化学物增加肿瘤细胞对化疗药物敏感性的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 67-72.
[10]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[11]	于芳, 赵培. TRAP1在食管癌发展中的作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 515-519.
[12]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[13]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[14]	阚钧, 周岱翰综述, 张恩欣审校. 肿瘤合并心血管疾病的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 558-561.
[15]	顾琦晟综述, 李继坤审校. 锰超氧化物歧化酶在肿瘤发生发展过程中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 562-566.

肿瘤多药耐药机制的研究进展

The research progress on cancer multidrug resistance mechanisms

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价